GlassScriptPhysician profile
Brian R Long
NPI 1245313741
$7,613.34
in general payments reported to CMS, 2019-2025
26 companies · $980 in 2025
The $980 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $558 · 2021: $833 · 2022: $1,250 · 2023: $1,948 · 2024: $912 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066 · Travel and Lodging: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,065.89 |
| Travel and Lodging | $774.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,121.60 | 2019-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Watchman Access System |
| Amgen INC. | $1,091.54 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $674.90 | 2019-2025 | |
| Shockwave Medical, INC | $640.82 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $593.00 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.60 | 2019-2023 | Jardiance |
| Abbott Laboratories | $306.29 | 2019-2024 | Amplatzer Amulet |
| Janssen Pharmaceuticals, INC | $208.02 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.61 | 2025 | |
| Sanofi-Aventis U.S. LLC | $183.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $181.11 | 2019-2023 | Farxiga |
| Alnylam Pharmaceuticals INC. | $135.77 | 2024-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $130.91 | 2021-2025 | Camzyos |
| Heartflow, INC. | $112.41 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $112.05 | 2023 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $95.49 | 2024 | Arcalyst |
| Novo Nordisk INC | $75.90 | 2023-2024 | Ozempic, Rybelsus |
| Chiesi USA, INC. | $61.04 | 2020-2021 | |
| Zoll Circulation INC | $49.11 | 2023 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Terumo Medical Corporation | $36.91 | 2019 | |
| Esperion Therapeutics, INC. | $34.66 | 2022 | |
| Cardinal Health 200 LLC | $18.69 | 2019 | |
| Amarin Pharma, INC. | $17.63 | 2019 | |
| Teleflex LLC | $16.93 | 2023 | Vascband |
| Penumbra, INC. | $10.00 | 2021 | |
| Bardy Diagnostics, INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.